Erschienen in:
01.01.2015 | Original Article—Alimentary Tract
Evaluation of serum HER2-ECD levels in patients with gastric cancer
verfasst von:
Katsunobu Oyama, Sachio Fushida, Tomoya Tsukada, Jun Kinoshita, Toshifumi Watanabe, Masatoshi Shoji, Shinichi Nakanuma, Koichi Okamoto, Seisho Sakai, Isamu Makino, Keishi Nakamura, Hironori Hayashi, Masafumi Inokuchi, Hisatoshi Nakagawara, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Hirohisa Kitagawa, Takashi Fujimura, Ryousuke Tajiri, Akishi Ooi, Tetsuo Ohta
Erschienen in:
Journal of Gastroenterology
|
Ausgabe 1/2015
Einloggen, um Zugang zu erhalten
Abstract
Background
Determination of the human epidermal growth factor receptor 2 (HER2) status of gastric cancer patients is indispensable in clinical practice. However, the clinical value of serum HER2-extracellular domain (ECD) in gastric cancer has not yet been defined.
Methods
The serum level of HER2-ECD was measured using the chemiluminescence immunoassay method, and its relationship with tissue HER2 status and clinicopathologic features was examined. Transition of serum HER2-ECD level was examined in patients during chemotherapy to clarify the correlation between changes in the level of HER2-ECD in serum and response to chemotherapy.
Results
A total of 150 gastric cancer patients were enrolled in this study; changes in HER2-ECD level were examined in 36 of these patients during chemotherapy. Serum levels of HER2-ECD ranged from 4.8 to 180.0 ng/ml (median 9.2 ng/ml) and were positive (cutoff value 15.2 ng/ml) in ten patients (6.7 %). There was a significant correlation between serum HER2-ECD level and tissue HER2 status (P < 0.001); however, no correlation with TNM stage was found. Change in serum HER2-ECD level during chemotherapy was significantly correlated with response to chemotherapy in patients with HER2-positive tumor tissue.
Conclusions
Serum HER2-ECD is a potential biomarker of gastric cancer and could be used as a diagnostic marker with regard to tissue HER2 status, and also as a monitoring marker in relation to response to chemotherapy.